Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00745251 · ClinicalTrials.gov registry record · Phase 1
A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults
A Phase 1 study, sponsored by VIVUS.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00745251 is a Phase 1 study that has completed, run by VIVUS. The registered enrollment target is 45 participants.
The verdict
NCT00745251, a Phase 1 study, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the safety and efficacy of VI-0521 compared to placebo in the treatment of obese adults with obstructive sleep apnea (OSA) and to assess the relative contributions of weight loss on parameters of OSA in these subjects.
Interventions
- DRUG placebo
- DRUG VI-0521
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00745251
The ClinicalTrials.gov registry entry for NCT00745251 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00745251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00745251 about?
NCT00745251 is a clinical study titled "A Study of VI-0521 for the Treatment of Obstructive Sleep Apnea / Hypopnea Syndrome in Obese Adults". The primary objectives of this study are to evaluate the safety and efficacy of VI-0521 compared to placebo in the treatment of obese adults with obstructive sleep apnea (OSA) and to assess the relative contributions of weight loss on parameters of OSA in these subjects.
What is the current status of trial NCT00745251?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2008-08. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00745251?
The interventions under investigation include: placebo (DRUG), VI-0521 (DRUG).
Who is sponsoring clinical trial NCT00745251?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.